Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Insider

AVBP

ArriVent BioPharma Inc.

May 17 • 04:00PM ET

20.10

Dollar change -0.05
Percentage change -0.25	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN SCHA IWO VTWO IWC SCHB RYLD

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	39.58%	Shs Outstand	33.49M	Perf Week	13.56%
Market Cap	673.15M	Forward P/E	-	EPS next Y	-2.74	Insider Trans	16.62%	Shs Float	20.24M	Perf Month	29.68%
Income	-96.02M	PEG	-	EPS next Q	-0.60	Inst Own	41.48%	Short Float	7.95%	Perf Quarter	-10.55%
Sales	0.00M	P/S	-	EPS this Y	90.89%	Inst Trans	-	Short Ratio	9.32	Perf Half Y	-
Book/sh	9.49	P/B	2.12	EPS next Y	7.02%	ROA	-	Short Interest	1.61M	Perf Year	-
Cash/sh	9.48	P/C	2.12	EPS next 5Y	-	ROE	-	52W Range	14.35 - 25.95	Perf YTD	0.50%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-30.21%	52W High	-22.54%	Beta	-
Dividend TTM	-	Quick Ratio	32.82	Sales past 5Y	0.00%	Gross Margin	-	52W Low	40.07%	ATR (14)	1.08
Dividend Ex-Date	-	Current Ratio	32.82	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	73.58	Volatility	6.30% 6.49%
Employees	40	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	30.20
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-66.77%	Payout	-	Rel Volume	0.38	Prev Close	20.15
Sales Surprise	-	EPS Surprise	35.02%	Sales Q/Q	-	Earnings	May 08 BMO	Avg Volume	172.64K	Price	20.10
SMA20	18.02%	SMA50	13.94%	SMA200	6.56%	Trades		Volume	65,380	Change	-0.25%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-24	Initiated	H.C. Wainwright	Buy	$25
Feb-20-24	Initiated	Jefferies	Buy	$35
Feb-20-24	Initiated	Goldman	Buy	$27
Feb-20-24	Initiated	Citigroup	Buy	$30

May-16-24 04:05PM	ArriVent Appoints John Hohneker, M.D., to its Board of Directors (GlobeNewswire)
May-08-24 12:54PM	AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	ArriVent BioPharma Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-22-24 04:05PM	ArriVent Appoints Kristine Peterson to its Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	ArriVent BioPharma Reports Full Year 2023 Financial Results (GlobeNewswire)
12:59PM	Loading…
Feb-05-24 12:59PM	Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Paul Tudor Jones, Julian Robertson, Charles Edwards, Arcus Biosciences, Inc. (RCUS), Arrivent Biopharma Inc (AVBP), and More (Insider Monkey)
Jan-25-24 09:30PM	ArriVent Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company. It focuses on identifying, licensing and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HILLHOUSE INVESTMENT MANAGEMEN	10% Owner	Jan 30 '24	Buy	18.00	555,555	9,999,990	4,484,672	Feb 01 04:47 PM
HEALY JAMES	Director	Jan 30 '24	Buy	18.00	444,444	7,999,992	1,696,752	Jan 31 04:10 PM
GORDON CARL L	Director	Jan 30 '24	Buy	18.00	444,444	7,999,992	1,513,664	Jan 31 04:11 PM
ORBIMED ADVISORS LLC	Director	Jan 30 '24	Buy	18.00	444,444	7,999,992	1,513,664	Jan 31 04:12 PM

AVBP

ArriVent BioPharma Inc.

Upgrade your FINVIZ experience